Zhitong Financial App News, Cansino Biotech (06185.HK) issued an announcement. The company has obtained a “Notice of Acceptance” from the China National Drug Administration (CNDA). According to the notice, the State Drug Administration has accepted a supplementary application to expand the applicable age range of the company's ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) (MCV4, trade name: Manhaixin®) from 3 months to 6 (83 years old) children.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.